OrbiMed Advisors TDOC Position
Exited3-Fund ConvergenceOrbiMed Advisors exited their position in Teladoc Health, Inc. (TDOC) in Q4 2023, after holding the stock for 2 quarters.
The position was first reported in Q3 2023 and has been tracked across 2 quarterly 13F filings.
TDOC is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 17.2% of float with 6.0 days to cover, indicating significant bearish positioning against the stock.
About Teladoc Health, Inc.
Teladoc Health, Inc. provides virtual healthcare services in the United States and internationally. The company offers a portfolio of services and solutions covering non-urgent, episodic, chronic, and complicated medical conditions, including diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and mental health conditions. It offers a range of programs and services, including primary and specialty care telehealth solutions, chronic condition management, expert medical services, mental health solutions, and platform and program services. The company serves employers, health plans, hospitals and health systems, and insurance and financial services companies, as well as individual members. It offers its products and services under the Teladoc, Livongo, and BetterHelp brands. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. The company was incorporated in 2002 and is headquartered in Purchase, New York.
Full company profile →Short Interest
17.2%
6.0 days to cover
OrbiMed Advisors TDOC Position History
Frequently Asked Questions
Does OrbiMed Advisors own TDOC?
No. OrbiMed Advisors exited their position in Teladoc Health, Inc. (TDOC) in Q4 2023. They previously held the stock for 2 quarters.
How many hedge funds own TDOC?
3 specialist biotech hedge funds currently hold TDOC, including Tang Capital Management, Casdin Capital, Deerfield Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy TDOC?
OrbiMed Advisors's position in TDOC was first reported in Q3 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's TDOC position increasing or decreasing?
OrbiMed Advisors completely exited their TDOC position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
TDOCCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →